San Antonio Breast Cancer Symposium
@sabcs.bsky.social
SABCS is the world's largest gathering of doctors, researchers and scientists sharing state-of-the-art information on experimental biology, etiology, prevention, diagnosis, and therapy for breast cancer and premalignant breast diseases. www.sabcs.org
#SABCSSnippets: Marcela Mazo talked with Marjolein Smidt at #SABCS25 about the results of the Phase III BOOG 2013-08 trial, which indicate that sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer.
buff.ly/MrXAKvF
buff.ly/MrXAKvF
January 2, 2026 at 4:44 PM
#SABCSSnippets: Marcela Mazo talked with Marjolein Smidt at #SABCS25 about the results of the Phase III BOOG 2013-08 trial, which indicate that sentinel lymph node biopsy may be safely omitted in some patients with early-stage breast cancer.
buff.ly/MrXAKvF
buff.ly/MrXAKvF
#SABCSSnippets: Saba Shaikh talked with Sonia Pernas at #SABCS25 about the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib + fulvestrant showed efficacy in HR+ metastatic breast cancer patients previously treated with a CDK4/6 inhibitor. buff.ly/gkjdRPf
December 30, 2025 at 3:44 PM
#SABCSSnippets: Saba Shaikh talked with Sonia Pernas at #SABCS25 about the Phase II SUMIT-BC trial, which showed that the CDK7 inhibitor samuraciclib + fulvestrant showed efficacy in HR+ metastatic breast cancer patients previously treated with a CDK4/6 inhibitor. buff.ly/gkjdRPf
Ruth O'Regan summarizes the 2025 FDA approvals for HR+ metastatic breast cancer, including datopotamab deruxtecan, trastuzumab deruxtecan, and imlunestrant. Watch now in the Best of #SABCS25:
buff.ly/vDfAHmH
buff.ly/vDfAHmH
December 23, 2025 at 7:13 PM
Ruth O'Regan summarizes the 2025 FDA approvals for HR+ metastatic breast cancer, including datopotamab deruxtecan, trastuzumab deruxtecan, and imlunestrant. Watch now in the Best of #SABCS25:
buff.ly/vDfAHmH
buff.ly/vDfAHmH
#SABCSSnippets: Rahul Gosain of the Oncology Brothers talked with Marleen Kok at #SABCS25 about how lobular carcinoma—which comprises 10-15% of all invasive breast cancers—differs from ductal carcinoma.
buff.ly/r4mA3Vx @marleenkok.bsky.social @oncbrothers.bsky.social
buff.ly/r4mA3Vx @marleenkok.bsky.social @oncbrothers.bsky.social
December 23, 2025 at 6:04 PM
#SABCSSnippets: Rahul Gosain of the Oncology Brothers talked with Marleen Kok at #SABCS25 about how lobular carcinoma—which comprises 10-15% of all invasive breast cancers—differs from ductal carcinoma.
buff.ly/r4mA3Vx @marleenkok.bsky.social @oncbrothers.bsky.social
buff.ly/r4mA3Vx @marleenkok.bsky.social @oncbrothers.bsky.social
Hope Rugo reviews biomarker subgroup results from the evERA phase III trial, updated EMBER-3 efficacy of imlunestrant in advanced breast cancer, and WISDOM 1.0 findings on risk-based screening. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH @hoperugo.bsky.social
December 22, 2025 at 3:58 PM
Hope Rugo reviews biomarker subgroup results from the evERA phase III trial, updated EMBER-3 efficacy of imlunestrant in advanced breast cancer, and WISDOM 1.0 findings on risk-based screening. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH @hoperugo.bsky.social
Hope Rugo shares the first positive results for an oral SERD (giredestrant) in the adjuvant setting and key findings from the phase III lidERA trial in ER+, HER2− early breast cancer. Watch now in the Best of #SABCS25:
https//buff.ly/fUHtwnq @hoperugo.bsky.social
https//buff.ly/fUHtwnq @hoperugo.bsky.social
December 19, 2025 at 7:02 PM
Hope Rugo shares the first positive results for an oral SERD (giredestrant) in the adjuvant setting and key findings from the phase III lidERA trial in ER+, HER2− early breast cancer. Watch now in the Best of #SABCS25:
https//buff.ly/fUHtwnq @hoperugo.bsky.social
https//buff.ly/fUHtwnq @hoperugo.bsky.social
#SABCSSnippets at #SABCS25: Julie Nangia and @ErikaHamilton9 discussed HER2CLIMB-05, which showed that adding tucatinib to 1st-line maintenance therapy with trastuzumab and pertuzumab delayed progression in patients with HER2+ metastatic breast cancer.
buff.ly/YIwYQEh @erikahamilton9.bsky.social
buff.ly/YIwYQEh @erikahamilton9.bsky.social
December 19, 2025 at 5:04 PM
#SABCSSnippets at #SABCS25: Julie Nangia and @ErikaHamilton9 discussed HER2CLIMB-05, which showed that adding tucatinib to 1st-line maintenance therapy with trastuzumab and pertuzumab delayed progression in patients with HER2+ metastatic breast cancer.
buff.ly/YIwYQEh @erikahamilton9.bsky.social
buff.ly/YIwYQEh @erikahamilton9.bsky.social
Janice Tsang reviews a year in metastatic breast cancer, highlighting key trial updates in TNBC, HER2+ and HR+/HER2− disease—including ASCENT, DESTINY-Breast, HER2CLIMB, EMBER-3 and SERENA-6. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH
December 18, 2025 at 6:02 PM
Janice Tsang reviews a year in metastatic breast cancer, highlighting key trial updates in TNBC, HER2+ and HR+/HER2− disease—including ASCENT, DESTINY-Breast, HER2CLIMB, EMBER-3 and SERENA-6. Watch now in the Best of #SABCS25: buff.ly/vDfAHmH
William Gradishar reviews key #SABCS25 findings in early breast cancer, including neoadjuvant trials TBCRC056 and OlympiA exploring PARP inhibitors and immunotherapy in BRCA-mutated disease. Watch now in the Best of SABCS®:
buff.ly/vDfAHmH
buff.ly/vDfAHmH
December 17, 2025 at 8:32 PM
William Gradishar reviews key #SABCS25 findings in early breast cancer, including neoadjuvant trials TBCRC056 and OlympiA exploring PARP inhibitors and immunotherapy in BRCA-mutated disease. Watch now in the Best of SABCS®:
buff.ly/vDfAHmH
buff.ly/vDfAHmH
#SABCSSnippets: Virginia Kaklamani talked with Hope Rugo at #SABCS25 about the field of endocrine therapy, including data from the Phase III evERA Breast Cancer Study and from the Phase II ELEVATE Study.
buff.ly/Bw3mSWW @vkaklamani.bsky.social @hoperugo.bsky.social
buff.ly/Bw3mSWW @vkaklamani.bsky.social @hoperugo.bsky.social
December 17, 2025 at 6:03 PM
#SABCSSnippets: Virginia Kaklamani talked with Hope Rugo at #SABCS25 about the field of endocrine therapy, including data from the Phase III evERA Breast Cancer Study and from the Phase II ELEVATE Study.
buff.ly/Bw3mSWW @vkaklamani.bsky.social @hoperugo.bsky.social
buff.ly/Bw3mSWW @vkaklamani.bsky.social @hoperugo.bsky.social
#SABCSSnippets: Virginia Kaklamani talked with Laura Esserman about the results of the WISDOM 1.0 study, which demonstrated that risk-based breast cancer screening is safe, preferred by women, and identifies the highest risk individuals.
buff.ly/DFByGvB @vkaklamani.bsky.social
buff.ly/DFByGvB @vkaklamani.bsky.social
December 15, 2025 at 4:53 PM
#SABCSSnippets: Virginia Kaklamani talked with Laura Esserman about the results of the WISDOM 1.0 study, which demonstrated that risk-based breast cancer screening is safe, preferred by women, and identifies the highest risk individuals.
buff.ly/DFByGvB @vkaklamani.bsky.social
buff.ly/DFByGvB @vkaklamani.bsky.social
Close out #SABCS25 with the Year in Review and View from the Trenches sessions on Friday afternoon.
More details in SABCS Meeting News: buff.ly/NMwi7Nk
More details in SABCS Meeting News: buff.ly/NMwi7Nk
December 12, 2025 at 7:09 PM
Close out #SABCS25 with the Year in Review and View from the Trenches sessions on Friday afternoon.
More details in SABCS Meeting News: buff.ly/NMwi7Nk
More details in SABCS Meeting News: buff.ly/NMwi7Nk
Experts will explore whether all patients with early-stage breast cancer need axillary staging during an #SABCS25 debate on Friday afternoon.
Learn more: buff.ly/dsX3CkF
Learn more: buff.ly/dsX3CkF
December 12, 2025 at 6:34 PM
Experts will explore whether all patients with early-stage breast cancer need axillary staging during an #SABCS25 debate on Friday afternoon.
Learn more: buff.ly/dsX3CkF
Learn more: buff.ly/dsX3CkF
Sara M. Tolaney, MD, MPH, AACR Outstanding Investigator Award for Breast Cancer Research recipient, will present an award lecture on Friday afternoon at #SABCS25.
Read more: buff.ly/Dnsf4Rd
Read more: buff.ly/Dnsf4Rd
December 12, 2025 at 5:53 PM
Sara M. Tolaney, MD, MPH, AACR Outstanding Investigator Award for Breast Cancer Research recipient, will present an award lecture on Friday afternoon at #SABCS25.
Read more: buff.ly/Dnsf4Rd
Read more: buff.ly/Dnsf4Rd
Friday's Poster Spotlight Sessions at #SABCS25 covered a wide range of topics, including the application of AI to pathology and risk stratification, locoregional challenges, and CNS metastases.
December 12, 2025 at 3:48 PM
Friday's Poster Spotlight Sessions at #SABCS25 covered a wide range of topics, including the application of AI to pathology and risk stratification, locoregional challenges, and CNS metastases.
#SABCS25 Patient Advocacy Spotlight: Marcela Mazo Canola, MD, and Laurel Pointer reflect on their relationship as physician and patient.
Read now in SABCS Meeting News: buff.ly/84wgwzX
Read now in SABCS Meeting News: buff.ly/84wgwzX
December 11, 2025 at 10:26 PM
#SABCS25 Patient Advocacy Spotlight: Marcela Mazo Canola, MD, and Laurel Pointer reflect on their relationship as physician and patient.
Read now in SABCS Meeting News: buff.ly/84wgwzX
Read now in SABCS Meeting News: buff.ly/84wgwzX
Real Impact with Artificial Intelligence:
Johan Hartman, Tufia Haddad, Amrita Basu, and advocate Carole L Baas explored this topic in an #SABCS25 educational session moderated by Frederick M Howard.
Johan Hartman, Tufia Haddad, Amrita Basu, and advocate Carole L Baas explored this topic in an #SABCS25 educational session moderated by Frederick M Howard.
December 11, 2025 at 10:05 PM
Real Impact with Artificial Intelligence:
Johan Hartman, Tufia Haddad, Amrita Basu, and advocate Carole L Baas explored this topic in an #SABCS25 educational session moderated by Frederick M Howard.
Johan Hartman, Tufia Haddad, Amrita Basu, and advocate Carole L Baas explored this topic in an #SABCS25 educational session moderated by Frederick M Howard.
Elie Rassy, Gustavo Werutsky, Sara Tolaney, and advocate Janice Cowden discussed "How to Treat TNBC" in an #SABCS25 educational session moderated by Marleen Kok.
December 11, 2025 at 9:52 PM
Elie Rassy, Gustavo Werutsky, Sara Tolaney, and advocate Janice Cowden discussed "How to Treat TNBC" in an #SABCS25 educational session moderated by Marleen Kok.
Patients are at the heart of the SABCS mission. We thank our patient advocate attendees for their enthusiastic participation in the Symposium and for their critical contributions to the #SABCS25 program.
December 11, 2025 at 9:31 PM
Patients are at the heart of the SABCS mission. We thank our patient advocate attendees for their enthusiastic participation in the Symposium and for their critical contributions to the #SABCS25 program.
Targeting the Non-T Cell Microenvironment: Fatima Mechta-Grigoriou, Kelly Kersten, George Plitas, and advocate Cheryl Jernigan addressed this topic in an #SABCS25 State of the Art session moderated by Christos Sotiriou.
December 11, 2025 at 9:12 PM
Targeting the Non-T Cell Microenvironment: Fatima Mechta-Grigoriou, Kelly Kersten, George Plitas, and advocate Cheryl Jernigan addressed this topic in an #SABCS25 State of the Art session moderated by Christos Sotiriou.
Management of the Axilla in Multidisciplinary Care: Giacomo Montagna, Lori Pierce, Sherry Shen, and advocate N. Beth Emery addressed this topic in an #SABCS25 Clinical Controversies session moderated by Tari A. King.
@sherryshenmd.bsky.social
@sherryshenmd.bsky.social
December 11, 2025 at 8:57 PM
Management of the Axilla in Multidisciplinary Care: Giacomo Montagna, Lori Pierce, Sherry Shen, and advocate N. Beth Emery addressed this topic in an #SABCS25 Clinical Controversies session moderated by Tari A. King.
@sherryshenmd.bsky.social
@sherryshenmd.bsky.social
Patient advocate Marissa Thomas, CEO of The Breast of Us, will speak during a Friday afternoon session at #SABCS25 on body image, hair loss, and skin health after cancer treatment.
Learn more in SABCS Meeting News: buff.ly/kVLAcSv
Learn more in SABCS Meeting News: buff.ly/kVLAcSv
December 11, 2025 at 8:29 PM
Patient advocate Marissa Thomas, CEO of The Breast of Us, will speak during a Friday afternoon session at #SABCS25 on body image, hair loss, and skin health after cancer treatment.
Learn more in SABCS Meeting News: buff.ly/kVLAcSv
Learn more in SABCS Meeting News: buff.ly/kVLAcSv
Wendy Woodward and François-Clément Bidard moderated today's General Session at #SABCS25. The clinical trials featured in the session included TBCRC-053, Alliance A011104/ACRIN 6694, and BOOG 2013-08.
@ibcradiation.bsky.social
@ibcradiation.bsky.social
December 11, 2025 at 7:16 PM
Wendy Woodward and François-Clément Bidard moderated today's General Session at #SABCS25. The clinical trials featured in the session included TBCRC-053, Alliance A011104/ACRIN 6694, and BOOG 2013-08.
@ibcradiation.bsky.social
@ibcradiation.bsky.social
Partnership for Progress:
#AACRFellows Dennis Slamon joined Debra A. Patt and Barbara Segarra-Vazquez to discuss the role of advocacy in breast cancer research and treatment during a special plenary lecture this morning at #SABCS25.
#AACRFellows Dennis Slamon joined Debra A. Patt and Barbara Segarra-Vazquez to discuss the role of advocacy in breast cancer research and treatment during a special plenary lecture this morning at #SABCS25.
December 11, 2025 at 6:48 PM
Partnership for Progress:
#AACRFellows Dennis Slamon joined Debra A. Patt and Barbara Segarra-Vazquez to discuss the role of advocacy in breast cancer research and treatment during a special plenary lecture this morning at #SABCS25.
#AACRFellows Dennis Slamon joined Debra A. Patt and Barbara Segarra-Vazquez to discuss the role of advocacy in breast cancer research and treatment during a special plenary lecture this morning at #SABCS25.
Another day of great science—including sessions on optimizing cardiac outcomes and treatment of triple-negative breast cancer, and the @theaacr.bsky.social Distinguished Lecture in Breast Cancer Research—will begin soon at #SABCS25.
December 11, 2025 at 1:12 PM
Another day of great science—including sessions on optimizing cardiac outcomes and treatment of triple-negative breast cancer, and the @theaacr.bsky.social Distinguished Lecture in Breast Cancer Research—will begin soon at #SABCS25.